{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Physical Examination Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.1",
        "sectionTitle": "Physical Examination",
        "description": "Reference for physical examination procedures"
      },
      {
        "id": "ref_2",
        "name": "Height/Weight/Performance Status Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.1",
        "sectionTitle": "Physical Examination",
        "description": "Reference for height, weight, ECOG/Karnofsky PS assessments"
      },
      {
        "id": "ref_3",
        "name": "Vital Signs Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.2",
        "sectionTitle": "Vital Signs",
        "description": "Reference for vital signs assessment procedures"
      },
      {
        "id": "ref_4",
        "name": "Resting O2 Saturation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.2",
        "sectionTitle": "Vital Signs",
        "description": "Reference for resting O2 saturation for SCCHN patients"
      },
      {
        "id": "ref_5",
        "name": "12-Lead ECG Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.3",
        "sectionTitle": "ECG Assessment",
        "description": "Reference for 12-Lead ECG procedures"
      },
      {
        "id": "ref_6",
        "name": "Blood Chemistry Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Laboratory Assessments",
        "description": "Reference to Table 12 for blood chemistry parameters"
      },
      {
        "id": "ref_7",
        "name": "Hematology Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Laboratory Assessments",
        "description": "Reference for hematology laboratory assessments"
      },
      {
        "id": "ref_8",
        "name": "Coagulation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Laboratory Assessments",
        "description": "Reference for coagulation assessments"
      },
      {
        "id": "ref_9",
        "name": "Blood Typing Interference Test Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Laboratory Assessments",
        "description": "Reference for blood typing interference test before each transfusion"
      },
      {
        "id": "ref_10",
        "name": "Serology Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Laboratory Assessments",
        "description": "Reference for HBV and HCV serology for HCC patients"
      },
      {
        "id": "ref_11",
        "name": "Urinalysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Laboratory Assessments",
        "description": "Reference for urinalysis and urine dipstick procedures"
      },
      {
        "id": "ref_12",
        "name": "Disease Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1",
        "sectionTitle": "Disease Assessment",
        "description": "Reference for CT/MRI disease assessment procedures"
      },
      {
        "id": "ref_13",
        "name": "Brain MRI Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1",
        "sectionTitle": "Disease Assessment",
        "description": "Reference for brain MRI for GBM patients"
      },
      {
        "id": "ref_14",
        "name": "Tumor Markers Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1",
        "sectionTitle": "Disease Assessment",
        "description": "Reference for AFP (HCC) and CA125 (EOC) tumor markers"
      },
      {
        "id": "ref_15",
        "name": "PK Flow Chart Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Pharmacokinetics and Immunogenicity Flow Chart",
        "description": "Reference to PK sampling schedule flow chart"
      },
      {
        "id": "ref_16",
        "name": "ADA Flow Chart Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Pharmacokinetics and Immunogenicity Flow Chart",
        "description": "Reference to ADA sampling schedule flow chart"
      },
      {
        "id": "ref_17",
        "name": "Biomarker Flow Chart Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Exploratory Biomarker Flow Chart",
        "description": "Reference to biomarker collection flow chart"
      },
      {
        "id": "ref_18",
        "name": "Laboratory Manual Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Laboratory Manual",
        "description": "Reference to laboratory manual for sample collection, processing and shipping"
      },
      {
        "id": "ref_19",
        "name": "Study Reference Manual",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Study Reference Manual",
        "description": "Reference to Study Reference Manual for adaptive immunity sample details"
      },
      {
        "id": "ref_20",
        "name": "I 02 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "I 02",
        "sectionTitle": "Appendix I 02",
        "description": "Reference for IHC analyses details"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "A cycle is 21 days",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 18
      },
      {
        "id": "annot_2",
        "text": "Informed consent may be signed prior to D -28",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Informed Consent",
        "pageNumber": 18
      },
      {
        "id": "annot_3",
        "text": "Women of child bearing potential must have a negative serum pregnancy test result within 7 days prior to first IMP administration",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Pregnancy Test",
        "pageNumber": 19
      },
      {
        "id": "annot_4",
        "text": "Evaluation not applicable for Cohort E",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Isatuximab Administration",
        "pageNumber": 20
      },
      {
        "id": "annot_5",
        "text": "Refer to the laboratory manual for sample collection, processing and shipping",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Pharmacokinetics and Immunogenicity Flow Chart",
        "pageNumber": 22
      },
      {
        "id": "annot_6",
        "text": "Isatuximab PK or ADA predose samples should be collected before isatuximab administration and at the same time as atezolizumab predose samples when applicable",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Pharmacokinetics and Immunogenicity Flow Chart",
        "pageNumber": 22
      },
      {
        "id": "annot_7",
        "text": "Atezolizumab sample collected strictly before the start of atezolizumab infusion (during treatment phase)",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Pharmacokinetics and Immunogenicity Flow Chart",
        "pageNumber": 22
      },
      {
        "id": "annot_8",
        "text": "P04 sample must be collected even if the participant withdraws the study without receiving the second administration of isatuximab",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Pharmacokinetics and Immunogenicity Flow Chart",
        "pageNumber": 22
      },
      {
        "id": "annot_9",
        "text": "After start of study treatment, if 1 drug is prematurely discontinued, ADA samples for this drug will be collected and tested on Day 1 of the 2 next cycles. The ADA sample collection for other drug should be done as planned",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Pharmacokinetics and Immunogenicity Flow Chart",
        "pageNumber": 22
      },
      {
        "id": "annot_10",
        "text": "Biomarker blood draw may be performed within 1 working day prior to IMP administration",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exploratory Biomarker Flow Chart",
        "pageNumber": 24
      },
      {
        "id": "annot_11",
        "text": "Mandatory for all GBM participants. For HCC, SCCHN, and EOC participants, provision of adequate archival tumor tissue is allowed to replace mandatory baseline biopsy",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exploratory Biomarker Flow Chart - Archival Tumor Tissue",
        "pageNumber": 24
      },
      {
        "id": "annot_12",
        "text": "At least 1 tumor core is required, but 3 cores are optimal. Refer to Laboratory Manual for details",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exploratory Biomarker Flow Chart - Tumor Biopsy",
        "pageNumber": 24
      },
      {
        "id": "annot_13",
        "text": "Only for Phase 2 Stage 2 participants",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exploratory Biomarker Flow Chart - Immunophenotyping",
        "pageNumber": 24
      },
      {
        "id": "annot_14",
        "text": "Only Phase 2 Stage 2 participants, if sufficient clinical response is observable in Phase 1 and Phase 2 Stage 1 participants",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exploratory Biomarker Flow Chart - Adaptive Immunity",
        "pageNumber": 24
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-11-23",
        "description": "Amended Clinical Trial Protocol 05 for ACT15377-isatuximab study",
        "amendmentNumber": "Amendment 05"
      }
    ],
    "summary": {
      "referenceCount": 20,
      "annotationCount": 14,
      "versionCount": 1
    }
  }
}